Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II olaparib study in PALB2-related advanced pancreatic cancer
2022-001094-32Phase 2Active
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib in pancreatic cancer (PC), sponsored by Azienda Ospedaliera Universitaria Policlinico. Primary endpoint: Objective response rate. Started Sep 2022; status: active.
02
Drugs
olaparib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2022-001094-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001094-32.